Jump to content
World's Largest Herpes Support Group
Sign in to follow this  
steel_panther

UB - 621

Recommended Posts

StayingUpbeat

UB-621 is a very odd offering into the HSV treatment landscape.  It's essentially a synthetically created antibody against the gD surface protein of both HSV-1 & 2.  The "drug" is specifically targeted toward a patient population that, for one reason or another, has a compromised immune system (i.e. HIV, Cancer, organ transplant) and drugs like acyclovir aren't getting the job done.

In theory by binding to the gD surface protein UB-621 will reduce the number of freely circulating HSV viral particles and reduce the number of recurrences while the compound is in your system. 

For people without a compromised immune system UB-621 would be a somewhat inappropriate treatment.

  1. It can only be administered via injection and would (notionally) need to be injected rather frequently
  2. If someone has a normal immune system it would already be creating antibodies against gD2
  3. It's efficacy in animal models is no better than the nucleoside analogs (acyclovir, valacyclovir, famvir)

 

Share this post


Link to post
Share on other sites
MikeHerp
Posted (edited)
On 12/13/2018 at 12:21 PM, StayingUpbeat said:

UB-621 is a very odd offering into the HSV treatment landscape.  It's essentially a synthetically created antibody against the gD surface protein of both HSV-1 & 2.  The "drug" is specifically targeted toward a patient population that, for one reason or another, has a compromised immune system (i.e. HIV, Cancer, organ transplant) and drugs like acyclovir aren't getting the job done.

In theory by binding to the gD surface protein UB-621 will reduce the number of freely circulating HSV viral particles and reduce the number of recurrences while the compound is in your system. 

For people without a compromised immune system UB-621 would be a somewhat inappropriate treatment.

  1. It can only be administered via injection and would (notionally) need to be injected rather frequently
  2. If someone has a normal immune system it would already be creating antibodies against gD2
  3. It's efficacy in animal models is no better than the nucleoside analogs (acyclovir, valacyclovir, famvir)

 

Are you sure it's only for immunocompromised patients?  Immunosuppression, cancer, or HIV positive status are exclusion criteria for the study.  I think this study is for "healthy people".

I wouldn't completely write it off, since it's gotten to phase 2.  Though, of course, I'm not holding my breath either.

Yes, it's by injection, but with the time frames being 112 days and 196 days for viral load and lesion rates), it suggests they hope that there is some lingering effects over time.

However, so far, they haven't even started recruiting, and with the study start date being listed as February, it seems they are behind schedule... if they ever even start.

Edited by MikeHerp

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

×

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.